WallStSmart

Dare Bioscience Inc (DARE)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Dare Bioscience Inc generates 56% more annual revenue ($1.16M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).

DARE

Avoid

23

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 3.5
Piotroski: 4/9Altman Z: -9.20

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DARE1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
499.6%10/10

Revenue surging 499.6% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

DARE4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$28.16M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Price/BookValuation
37.6x2/10

Trading at 37.6x book value

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DARE

The strongest argument for DARE centers on Revenue Growth. Revenue growth of 499.6% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : DARE

The primary concerns for DARE are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 9.78 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

DARE profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

DARE is growing revenue faster at 499.6% — sustainability is the question.

DARE generates stronger free cash flow (-6M), providing more financial flexibility.

Bottom Line

RVMD scores higher overall (24/100 vs 23/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dare Bioscience Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. The company is headquartered in San Diego, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?